Cyanidin is an agonistic ligand for peroxisome proliferator-activated receptor-alpha reducing hepatic lipid

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1831, Issue 4, 2013, Pages 698-708

  Jia, Yaoyao ^a   Kim, Jin Young ^a   Jun, Hee Jin ^a   Kim, Sun Joong ^a   Lee, Ji Hae ^a   Hoang, Minh Hien ^a   Kim, Hyun Sook ^a   Chang, Hyo Ihl ^a   Hwang, Kwang Yeon ^a   Um, Soo Jong ^b   Lee, Sung Joon ^a  

^a Korea University   (South Korea)

^b Sejong University   (South Korea)

Author keywords

Cyanidin; Hepatocyte; Lipid metabolism; PPAR

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTOME;

ARTICLE; GENE EXPRESSION; HUMAN; HYPOLIPEMIA; LIPID LIVER LEVEL; LIPID METABOLISM; LIVER CELL; PRIORITY JOURNAL; REPORTER GENE; SURFACE PLASMON RESONANCE;

ANIMALS; ANTHOCYANINS; CELLS, CULTURED; CHO CELLS; CRICETINAE; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIPID METABOLISM; PPAR ALPHA; PPAR GAMMA; PPAR-BETA;

EID: 84873451171     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2012.11.012     Document Type: Article

References (57)

1. S. Kersten, B. Desvergne, and W. Wahli Roles of PPARs in health and disease Nature 405 2000 421 424
2. V. Bocher, I. Pineda-Torra, J.C. Fruchart, and B. Staels PPARs: transcription factors controlling lipid and lipoprotein metabolism Ann. N. Y. Acad. Sci. 967 2002 7 18
3. C.F. Semenkovich Insulin resistance and atherosclerosis J. Clin. Invest. 116 2006 1813 1822
4. J.F. Viles-Gonzalez, B.G. Choi, V. Fuster, and J.J. Badimon Peroxisome proliferator-activated receptor ligands in atherosclerosis Expert Opin. Investig. Drugs 13 2004 1393 1403
5. A. Ciudin, C. Hernandez, and R. Simo Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology Curr. Top. Med. Chem. 12 2012 585 604
6. P. Shah, and S. Mudaliar Pioglitazone: side effect and safety profile Expert Opin. Drug Saf. 9 2010 347 354
7. P.L. Feldman, M.H. Lambert, and B.R. Henke PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Curr. Top. Med. Chem. 8 2008 728 749
8. J.A. Ross, and C.M. Kasum Dietary flavonoids: bioavailability, metabolic effects, and safety Annu. Rev. Nutr. 22 2002 19 34
9. F. Galvano, L. La Fauci, G. Lazzarino, V. Fogliano, A. Ritieni, S. Ciappellano, N.C. Battistini, B. Tavazzi, and G. Galvano Cyanidins: metabolism and biological properties J. Nutr. Biochem. 15 2004 2 11
10. A.S. Meyer, M. Heinonen, and E.N. Frankel Antioxidant interactions of catechin, cyanidin, caffeic acid, quercetin, and ellagic acid on human LDL oxidation Food Chem. 61 1998 71 75
11. A.M. Amorini, G. Fazzina, G. Lazzarino, B. Tavazzi, D. Di Pierro, R. Santucci, F. Sinibaldi, F. Galvano, and G. Galvano Activity and mechanism of the antioxidant properties of cyanidin-3-O-beta-glucopyranoside Free Radic. Res. 35 2001 953 966
12. A.R. Abdel-Moemin Switching to black rice diets modulates low-density lipoprotein oxidation and lipid measurements in rabbits Am. J. Med. Sci. 341 2011 318 324
13. M. Kamiyama, Y. Kishimoto, M. Tani, K. Andoh, K. Utsunomiya, and K. Kondo Inhibition of low-density lipoprotein oxidation by Nagano purple grape (Vitis viniferaxVitis labrusca) J. Nutr. Sci. Vitaminol. (Tokyo) 55 2009 471 478
14. Y. Qin, M. Xia, J. Ma, Y. Hao, J. Liu, H. Mou, L. Cao, and W. Ling Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects Am. J. Clin. Nutr. 90 2009 485 492
15. S. Valcheva-Kuzmanova, K. Kuzmanov, V. Mihova, I. Krasnaliev, P. Borisova, and A. Belcheva Antihyperlipidemic effect of Aronia melanocarpa fruit juice in rats fed a high-cholesterol diet Plant Foods Hum. Nutr. 62 2007 19 24
16. C. Auger, B. Caporiccio, N. Landrault, P.L. Teissedre, C. Laurent, G. Cros, P. Besancon, and J.M. Rouanet Red wine phenolic compounds reduce plasma lipids and apolipoprotein B and prevent early aortic atherosclerosis in hypercholesterolemic golden Syrian hamsters (Mesocricetus auratus) J. Nutr. 132 2002 1207 1213
17. K. Decorde, P.L. Teissedre, T. Sutra, E. Ventura, J.P. Cristol, and J.M. Rouanet Chardonnay grape seed procyanidin extract supplementation prevents high-fat diet-induced obesity in hamsters by improving adipokine imbalance and oxidative stress markers Mol. Nutr. Food Res. 53 2009 659 666
18. C. Dallas, A. Gerbi, G. Tenca, F. Juchaux, and F.X. Bernard Lipolytic effect of a polyphenolic citrus dry extract of red orange, grapefruit, orange (SINETROL) in human body fat adipocytes. Mechanism of action by inhibition of cAMP-phosphodiesterase (PDE) Phytomedicine 15 2008 783 792
19. L. Janderova, M. McNeil, A.N. Murrell, R.L. Mynatt, and S.R. Smith Human mesenchymal stem cells as an in vitro model for human adipogenesis Obes. Res. 11 2003 65 74
20. D. Teupser, J. Thiery, A.K. Walli, and D. Seidel Determination of LDL- and scavenger-receptor activity in adherent and non-adherent cultured cells with a new single-step fluorometric assay BBA-Lipids Lipid Metab. 1303 1996 193 198
21. Y. Jia, M.J. Bhuiyan, H.J. Jun, J.H. Lee, M.H. Hoang, H.J. Lee, N. Kim, D. Lee, K.Y. Hwang, B.Y. Hwang, D.W. Choi, and S.J. Lee Ursolic acid is a PPAR-alpha agonist that regulates hepatic lipid metabolism Bioorg. Med. Chem. Lett. 21 2011 5876 5880
22. S. Ban, J. Kasuga, I. Nakagome, H. Nobusada, F. Takayama, S. Hirono, H. Kawasaki, Y. Hashimoto, and H. Miyachi Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) alpha-selective agonists Bioorg. Med. Chem. 19 2011 3183 3191
23. F. Mohamadi, N.G.J. Richards, W.C. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. Hendrickson, and W.C. Still Macromodel - an Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics J. Comput. Chem. 11 1990 440 467
24. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, and P.S. Shenkin Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 47 2004 1739 1749
25. M. Ashburner, C.A. Ball, J.A. Blake, D. Botstein, H. Butler, J.M. Cherry, A.P. Davis, K. Dolinski, S.S. Dwight, J.T. Eppig, M.A. Harris, D.P. Hill, L. Issel-Tarver, A. Kasarskis, S. Lewis, J.C. Matese, J.E. Richardson, M. Ringwald, G.M. Rubin, and G. Sherlock Gene ontology: tool for the unification of biology. The Gene Ontology Consortium Nat. Genet. 25 2000 25 29
26. S. Goto, T. Nishioka, and M. Kanehisa LIGAND: chemical database of enzyme reactions Nucleic Acids Res. 28 2000 380 382
27. M. Kanehisa, and S. Goto KEGG: kyoto encyclopedia of genes and genomes Nucleic Acids Res. 28 2000 27 30
28. M. Reich, T. Liefeld, J. Gould, J. Lerner, P. Tamayo, and J.P. Mesirov GenePattern 2.0 Nat. Genet. 38 2006 500 501
29. C.Y. Lin, S.J. Tsai, C.S. Huang, and M.C. Yin Antiglycative effects of protocatechuic acid in the kidneys of diabetic mice J. Agric. Food Chem. 59 2011 5117 5124
30. P. Balakumar, M. Rose, S.S. Ganti, P. Krishan, and M. Singh PPAR dual agonists: Are they opening Pandora's box? Pharmacol. Res. 56 2007 91 98
31. C. Fievet, J.C. Fruchart, and B. Staels PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome Curr. Opin. Pharmacol. 6 2006 606 614
32. V. Zoete, A. Grosdidier, and O. Michielin Peroxisome proliferator- activated receptor structures: ligand specificity, molecular switch and interactions with regulators Biochim. Biophys. Acta 1771 2007 915 925
33. P. Markt, D. Schuster, J. Kirchmair, C. Laggner, and T. Langer Pharmacophore modeling and parallel screening for PPAR ligands J. Comput. Aided Mol. Des. 21 2007 575 590
34. T. Oyama, K. Toyota, T. Waku, Y. Hirakawa, N. Nagasawa, J.I. Kasuga, Y. Hashimoto, H. Miyachi, and K. Morikawa Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures Acta Crystallogr. D Biol. Crystallogr. 65 2009 786 795
35. R.L. Prior Fruits and vegetables in the prevention of cellular oxidative damage Am. J. Clin. Nutr. 78 2003 570S 578S
36. A. Fredenrich, and P.A. Grimaldi PPAR delta: an uncompletely known nuclear receptor Diabetes Metab. 31 2005 23 27
37. E. Robinson, and D.J. Grieve Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease Pharmacol. Ther. 122 2009 246 263
38. T. Yamauchi, J. Kamon, H. Waki, K. Murakami, K. Motojima, K. Komeda, T. Ide, N. Kubota, Y. Terauchi, K. Tobe, H. Miki, A. Tsuchida, Y. Akanuma, R. Nagai, S. Kimura, and T. Kadowaki The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance J. Biol. Chem. 276 2001 41245 41254
39. C. Postic, and J. Girard Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice J. Clin. Invest. 118 2008 829 838
40. P. Lefebvre, G. Chinetti, J.C. Fruchart, and B. Staels Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis J. Clin. Invest. 116 2006 571 580
41. E.R. Kallwitz, A. McLachlan, and S.J. Cotler Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease World J. Gastroenterol. 14 2008 22 28
42. J.H. de Vries, P.C. Hollman, S. Meyboom, M.N. Buysman, P.L. Zock, W.A. van Staveren, and M.B. Katan Plasma concentrations and urinary excretion of the antioxidant flavonols quercetin and kaempferol as biomarkers for dietary intake Am. J. Clin. Nutr. 68 1998 60 65
43. P.C. Hollman, J.H. de Vries, S.D. van Leeuwen, M.J. Mengelers, and M.B. Katan Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers Am. J. Clin. Nutr. 62 1995 1276 1282
44. P.C. Hollman, J.M. van Trijp, M.N. Buysman, M.S. van der Gaag, M.J. Mengelers, J.H. de Vries, and M.B. Katan Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man FEBS Lett. 418 1997 152 156
45. L. Gerez, K. Mohrmann, M. van Raak, M. Jongeneelen, X.Z. Zhou, K.P. Lu, and P. van Der Sluijs Accumulation of rab4GTP in the cytoplasm and association with the peptidyl-prolyl isomerase pin1 during mitosis Mol. Biol. Cell 11 2000 2201 2211
46. J.H. de Vries, P.C. Hollman, I. van Amersfoort, M.R. Olthof, and M.B. Katan Red wine is a poor source of bioavailable flavonols in men J. Nutr. 131 2001 745 748
47. A. Maestro, M. Terdoslavich, A. Vanzo, A. Kuku, F. Tramer, V. Nicolin, F. Micali, G. Decorti, and S. Passamonti Expression of bilitranslocase in the vascular endothelium and its function as a flavonoid transporter Cardiovasc. Res. 85 2010 175 183
48. A. Dreiseitel, B. Oosterhuis, K.V. Vukman, P. Schreier, A. Oehme, S. Locher, G. Hajak, and P.G. Sand Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1 Br. J. Pharmacol. 158 2009 1942 1950
49. A. Aszalos Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs Curr. Drug Metab. 9 2008 1010 1018
50. L. Ziberna, F. Tramer, S. Moze, U. Vrhovsek, F. Mattivi, and S. Passamonti Transport and bioactivity of cyanidin 3-glucoside into the vascular endothelium Free Radic. Biol. Med. 52 2012 1750 1759
51. A. Vanzo, U. Vrhovsek, F. Tramer, F. Mattivi, and S. Passamonti Exceptionally fast uptake and metabolism of cyanidin 3-glucoside by rat kidneys and liver J. Nat. Prod. 74 2011 1049 1054
52. F. Galvano, L. La Fauci, P. Vitaglione, V. Fogliano, L. Vanella, and C. Felgines Bioavailability, antioxidant and biological properties of the natural free-radical scavengers cyanidin and related glycosides Ann. Ist. Super. Sanita 43 2007 382 393
53. J. Oidtmann, M. Schantz, K. Mader, M. Baum, S. Berg, M. Betz, U. Kulozik, S. Leick, H. Rehage, K. Schwarz, and E. Richling Preparation and comparative release characteristics of three anthocyanin encapsulation systems J. Agric. Food Chem. 60 2012 844 851
54. F. Gandia-Herrero, M. Jimenez-Atienzar, J. Cabanes, F. Garcia-Carmona, and J. Escribano Stabilization of the bioactive pigment of opuntia fruits through maltodextrin encapsulation J. Agric. Food Chem. 58 2010 10646 10652
55. J. Duconge, J.R. Miranda-Massari, M.J. Gonzalez, J.A. Jackson, W. Warnock, and N.H. Riordan Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate P. R. Health Sci. J. 27 2008 7 19
56. P. Vitaglione, G. Donnarumma, A. Napolitano, F. Galvano, A. Gallo, L. Scalfi, and V. Fogliano Protocatechuic acid is the major human metabolite of cyanidin-glucosides J. Nutr. 137 2007 2043 2048
57. B. Scazzocchio, R. Vari, C. Filesi, M. D'Archivio, C. Santangelo, C. Giovannini, A. Iacovelli, G. Silecchia, G. Li Volti, F. Galvano, and R. Masella Cyanidin-3-O-beta-glucoside and protocatechuic acid exert insulin-like effects by upregulating PPARgamma activity in human omental adipocytes Diabetes 60 2011 2234 2244